We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RXi and miRagen Announce Formation of Research Collaboration in the Field of microRNAs
News

RXi and miRagen Announce Formation of Research Collaboration in the Field of microRNAs

RXi and miRagen Announce Formation of Research Collaboration in the Field of microRNAs
News

RXi and miRagen Announce Formation of Research Collaboration in the Field of microRNAs

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RXi and miRagen Announce Formation of Research Collaboration in the Field of microRNAs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

RXi Pharmaceuticals Corporation and miRagen Therapeutics, Inc. have announced that they have entered into a research collaboration.

Under this agreement, the parties will evaluate the potential utility of RXi’s proprietary rxRNA™ technology against specific miRNA targets of interest to miRagen in the cardiac and neuromuscular disease areas. Each party will contribute its technology and resources to the collaboration to generate novel miRNA compounds. Financial terms of the collaboration were not disclosed.

“We look forward to working with miRagen in exploring the potential of validating our proprietary rxRNA compounds in the field of miRNA, as success with this approach may allow us to expand the utility of RXi’s therapeutic platform, as well as the commercial scope of product opportunities.”

“miRNAs, which are natural RNAi triggers, have been recently implicated in a variety of human diseases, including cancer, inflammation, as well as metabolic and cardiovascular disorders,” said Noah Beerman, President and Chief Executive Officer of RXi. “We look forward to working with miRagen in exploring the potential of validating our proprietary rxRNA compounds in the field of miRNA, as success with this approach may allow us to expand the utility of RXi’s therapeutic platform, as well as the commercial scope of product opportunities.”

“miRagen is committed to evaluating and deploying the most advanced technologies available to support our mission of developing microRNA-based therapeutics,” said William S. Marshall, Ph.D., President and CEO of miRagen Therapeutics. “We are enthusiastic about the potential for the rxRNA technology to produce miRNA mimicry and thus are keenly interested in working with RXi to further investigate its properties.”
Advertisement